NCT03441555 - A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

January 25, 2021

Study Completion Date

January 25, 2021

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

Venetoclax

tablet, oral

DRUG

Alvocidib

Intravenous

Trial Locations (14)

Weill Cornell Medical College /ID# 170800, New York

University of Pittsburgh Medic /ID# 170790, Pittsburgh

Univ Klinik Eppendorf Hamburg /ID# 168633, Hamburg

Indiana Blood & Marrow Transpl /ID# 170793, Indianapolis

USC Norris Cancer Center /ID# 170844, Los Angeles

UC Irvine /ID# 201093, Orange

University of California, Davis Comprehensive Cancer Center /ID# 170799, Sacramento

Sylvester Comprehensive Cancer /ID# 170761, Miami

NYU Langone Medical Center /ID# 201559, New York

Duke University Medical Center /ID# 170842, Durham

Universitaetsklinikum Dresden /ID# 168636, Dresden

University Hospital of Wales /ID# 202302, Cardiff

Ninewells Hospital /ID# 202304, Dundee

St. James University Hospital /ID# 202303, Leeds